Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema (Q35575496)

8 August 2017

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema (English)

1 reference

8 August 2017

1 reference

1 reference

diabetic macular edema

1 reference

Diabetic Retinopathy Clinical Research Network

inferred from title

author

1

object named as

Diabetic Retinopathy Clinical Research Network

1 reference

8 August 2017

3

Adam R Glassman

1 reference

8 August 2017

5

Lee M Jampol

1 reference

8 August 2017

10

Neil M Bressler

1 reference

8 August 2017

18

Roy W Beck

1 reference

8 August 2017

John A Wells

2

1 reference

8 August 2017

Allison R Ayala

4

1 reference

8 August 2017

Lloyd Paul Aiello

6

1 reference

8 August 2017

Andrew N Antoszyk

7

1 reference

8 August 2017

Bambi Arnold-Bush

8

1 reference

8 August 2017

Carl W Baker

9

1 reference

8 August 2017

David J Browning

11

1 reference

8 August 2017

Michael J Elman

12

1 reference

8 August 2017

Frederick L Ferris

13

1 reference

8 August 2017

Scott M Friedman

14

1 reference

8 August 2017

Michele Melia

15

1 reference

8 August 2017

Dante J Pieramici

16

1 reference

8 August 2017

Jennifer K Sun

17

1 reference

8 August 2017

language of work or name

English

0 references

publication date

18 February 2015

1 reference

The New England Journal of Medicine

8 August 2017

1 reference

8 August 2017

372

1 reference

8 August 2017

1193-1203

1 reference

8 August 2017

13

1 reference

Anti-vascular endothelial growth factor for diabetic macular oedema

8 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4422053

Evaluation of compounded bevacizumab prepared for intravitreal injection

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4422053

Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4422053

Prevalence of and risk factors for diabetic macular edema in the United States

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4422053

Reproducibility of spectral-domain optical coherence tomography retinal thickness measurements and conversion to equivalent time-domain metrics in diabetic macular edema

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4422053

Intravitreal aflibercept for diabetic macular edema

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4422053

Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4422053

Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the Pan-american Collaborative Retina Study Group at 24 months

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4422053

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4422053

One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4422053

A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4422053

Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4422053

Lasting controversy on ranibizumab and bevacizumab

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4422053

The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4422053

Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4422053

Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4422053

A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4422053

Resource use and costs associated with diabetic macular edema in elderly persons

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4422053

A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4422053

Ranibizumab for neovascular age-related macular degeneration

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4422053

Multiple imputation: a primer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4422053

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4422053

Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4422053

Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4422053

A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4422053

Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials

26 September 2018

1 reference

12 December 2020

Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors

1 reference

12 December 2020

More on influenza vaccine in young children

1 reference

12 December 2020

Easy SAS calculations for risk or prevalence ratios and differences

1 reference

12 December 2020

Identifiers

DOI

10.1056/NEJMOA1414264

1 reference

8 August 2017

1 reference

8 August 2017

1 reference